You are here

Biogen

For Eisai and Biogen's Leqembi, first FDA-approved Alzheimer's blood test will take time to boost launch: analyst

Fierce Pharma

Mon, 05/19/25 - 10:25 pm

Alzheimer's disease

Biogen earnings beat by $0.06, revenue topped estimates

Investing.com

Thu, 05/1/25 - 09:54 am

Leqembi is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

Stock Titan

Tue, 04/15/25 - 07:49 pm

Alzheimer's disease

Five Biggest Drug Face-Offs in Pharma History

BioSpace

Wed, 04/9/25 - 11:38 am

Bristol Myers Squibb

US vs. EU: When it comes to novel Alzheimer’s drugs, regulators can’t seem to agree

Pharma Voice

Mon, 04/7/25 - 10:06 am

Alzheimer's disease

FDA Grants Fast Track Designation to Biogen’s Novel Alzheimer Disease Drug Candidate

Pharm Exec

Thu, 04/3/25 - 11:28 am

Alzheimer's disease

Biogen plots 2028 headquarters shift to new 'innovation hub' in Cambridge

Fierce Pharma

Mon, 03/24/25 - 11:07 am

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Drugs.com

Tue, 03/11/25 - 06:57 pm

clinical trials

kidney translants

What’s driving pharma’s layoffs in 2025

Pharma Voice

Mon, 03/10/25 - 09:27 am

CRISPR Therapeutics

Atara Biotherapeutics

Bristol Myers Squibb

Biogen, Apple study finds smart devices can track cognition

Pharmaphorum

Fri, 03/7/25 - 11:07 am

cognitive impairment

NICE agrees to look again at Alzheimer's drug Leqembi

Pharmaphorum

Thu, 03/6/25 - 10:59 am

Alzheimer's disease

New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer’s approach

Pharma Voice

Tue, 03/4/25 - 09:51 am

Voyager Therapeutics

Alzheimer's disease

Australia stands firm on 'no' to Alzheimer's drug Leqembi

Pharmaphorum

Mon, 03/3/25 - 10:53 am

Alzheimer's disease

Leqembi, after delay, gets back on track toward EU approval

BioPharma Dive

Sun, 03/2/25 - 09:35 pm

Alzheimer's disease

Biogen pays Stoke $165M, bagging Dravet prospect to fire up late-phase pipeline

Fierce Biotech

Tue, 02/18/25 - 11:12 am

Stoke Therapeutics

Dravet syndrome

Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short

CNBC

Wed, 02/12/25 - 11:08 am

Biogen enlists Royalty for pursuit of lupus crown, securing $250M to fund phase 3 program

Fierce Biotech

Wed, 02/12/25 - 10:03 am

Europe to review safety data for Eisai-Biogen Alzheimer's drug

Marketscreener

Fri, 01/31/25 - 11:16 am

Alzheimer's disease

Sage rejects Biogen's $469 million takeover offer, says offer undervalues company

Yahoo/Reuters

Mon, 01/27/25 - 11:38 am

SAGE Therapeutics

Biogen, Eisai Win Nod for Monthly Leqembi Maintenance Amid Stagnant Sales

BioPharma Dive

Mon, 01/27/25 - 11:24 am

Alzheimer's disease

Pages